Ann: CAN-003 INTERIM ANALYSIS PRESENTATION , page-15

""Boiler I cant understand the game you're playing here.""

eagle I'm not playing a game, I answered your request yesterday with my opinion which was correct, I called it 3 and a half months ago and was shouted down as I was yesterday. I continue to post because you respond, and I will defend my opinion because it is correct and your efforts to communicate with the company hype the trial results and ICS data etc etc all equated to zilch in regards to shareprice appreciation.

Yes eagle the market cap in higher , you best hope they achieve their goals to the markets satisfaction.

Last post for today, enough banter for now, have a great day.

The call three and a half month ago eagle for what it's worth,without phoning a friend..........


""re: prima biomed to release interim cvac clinical (boiler)
Post: 8372803
Reply to: #8368628 from eagle888 Views: 1013
Posted: 02/08/12 11:57 Stock Price (at time of posting): 12c


eagle888 thanks for keeping me upto date with wasting you time reposting all those asx announcements with all the nice green tu's to go with it lol. Lots of green on the prr thread, pitty it's not reflected in the shareprice , I wonder why.

eagle you call it downramping, I call it research.......

See if you get the picture he guys.....ASX announcement 4 days ago......

""ICS is a laboratory technique to evaluate if CVac has induced the desired mucin 1-specific T-cell response in treated patients. ICS results help to confirm the biological activity of CVac. Positive ICS results would validate the continuing development in ovarian cancer trials and potentially pave the way for Prima to commence exploratory trials in other cancer types that overexpress mucin-1.""

ASX announcement 10 years ago(2002 Annual Report).......

""MANNAN ADJUVANT TECHNOLOGY
Immunological adjuvants can play a key role in the type, strength
and persistence of immune responses following immunisation with
specific antigens. Many adjuvants are able to stimulate the B cell
(antibody) arm of the immune system, but far fewer are able to
effectively stimulate effective T cell (cellular) immune responses.
Cancer Vac has shown that the attachment of antigens to mannan
(polymannose) enables the stimulation of cellular immune
responses (cytotoxic T lymphocytes (CTL’s)) to the antigen.
Cancer Vac has focused on the antigen mucin 1 (MUC1). Mucins
are present on normal cells but are expressed at significantly
higher levels in breast, ovarian & pancreatic cancer. Cancer
Vac technology combines mannan and MUC1 to create the
mannan-MAC1 stimulant.
Earlier studies, direct immunisation of subjects failed to induce
significant cellular immune responses. Subsequently, we have
assessed the ability of the mannan – MUC1 conjugate to effectively
prime isolated DCs, which are then re-injected into the patients.
Using this strategy we have seen a significant improvement, with
cellular immune responses to MUC1 produced in all patients that
have completed treatment.
Preliminary data generated from an ongoing clinical trial in cancer
patients, evaluating ex vivo priming of DCs with the vaccine, has
demonstrated that mannan – MUC1 primed DCs are well tolerated
following re-injection into patients and that all patients who have
completed treatment and follow-up evaluation have developed
strong antigen (MUC1)-specific T cell responses. This can be
demonstrated by showing the increasing number of MUC1-specific
T cells in the circulation of patients following treatment.""